Skip to content

Collection of Autologous Blood Products by Double Erythrocytapheresis

Collection of Autologous Blood Products by Double Erythrocytapheresis - Cost Effectiveness Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00202475
Enrollment
100
Registered
2005-09-20
Start date
2003-09-30
Completion date
2007-12-31
Last updated
2009-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre Operative Autologous Donation

Keywords

Dubble eerythrocytapheresis

Brief summary

The project will determine the advantages of double erythrocytapheresis in the collection of preoperative autologous erythrocytes as compared to the standard collections of whole blood. The study will assess the total reduction in the number of procedures required to obtain the preoperative units ordered by the surgeon. Also, successfulness of erythrocytaphereses versus classical whole blood collection for these patients will be compared.

Detailed description

The project will determine the advantages of double erythrocytapheresis in the collection of preoperative autologous erythrocytes as compared to the standard collections of whole blood. The study will assess the total reduction in the number of procedures required to obtain the preoperative units ordered by the surgeon. Also, successfulness of erythrocytaphereses versus classical whole blood collection for these patients will be compared.

Interventions

PROCEDUREeythrocytapheresis

machinal collection of erythrocytes

collection of whole blood

Sponsors

Atrium Medical Center
CollaboratorOTHER
Maasland Hospital
CollaboratorOTHER
Sanquin Research & Blood Bank Divisions
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elective surgery

Exclusion criteria

* Malignancies * Severe arrhythmias * Congestive heart failure * Recent angina * Epileptic seizures in the last 3 months before collection

Design outcomes

Primary

MeasureTime frame
decline in Hemoglobine levelssurgery

Secondary

MeasureTime frame
Storage parameters- ATP35 days

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026